Bacterial sphingolipids - revealing hidden biosynthetic pathways of key players in host-microbe interactions.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Sphingolipids (SLs) and ceramides play essential roles in membrane structure and cell signalling. They are found in yeast, plants, mammals and some bacteria (e.g. human microbiota). The microbiota has gained attention since be linked to maintaining human health. Recently, members of the microbiota (Bacteroides, P. gingivalis) have been shown to produce SLs that mediate interactions with host cells. In contrast to higher eukaryotes, very little is known about microbial SL biosynthesis, regulation and transport. To fully understand the molecular details of the SL-mediated microbiota/human interaction we must first decipher the mechanisms that govern the biosynthesis and metabolism of these molecules. Our hypothesis is that the microbes of the human microbiota make sphingolipids by a novel biosynthetic pathway that shares common elements derived from prokaryotes and eukaryotes.
The chemical structure of a mature bacterial SL (such as galactosylceramide, GSL) suggests a concise biosynthetic pathway that draws precursors (amino acids, fatty acids and sugars) from primary metabolism. The microbiota GSL contains a diagnostic iso-Me branched fingerprint in the fatty acid moiety of the SLs. This suggests a number of key steps catalysed by a suite of interesting enzymes which will be the focus of our study. Specifically we will target three key steps in the pathway; firstly, the crucial enzyme serine palmitoyltransferase (SPT) that combines L-serine and fatty acids to form the SL backbone; secondly, identify the origin of the branched-chain fingerprint of microbiota SLs; and thirdly, characterise the enzyme that converts glucose 6-phosphate to inositol phosphate which generates complex inositol SLs in certain bacteria. In collaboration with experts in microbiology and structural biology we will use protein chemistry, enzyme assay, analytical chemistry, X-ray crystallography, genetic screens and mutagenesis as tools to deliver our aim to map bacterial SL biosynthesis.

Wider beneficiaries
This project will have far reaching impacts with a wide group of beneficiaries. As well as the training opportunities for our team of UK-based scientists in microbiology, protein biochemistry and structural biology, we will interact closely with our European (Ley) and USA project partners (Davey & Dunn) to transfer knowledge and expertise between our research groups. Our link with Lipid Maps will spread our results to >65000 members.
The key role of the microbiota in human and animal health and wellbeing is undisputed, and there is growing evidence that bacterial sphingolipids have a significant impact on host-microbiota tolerance and the development and maturation of the immune system. The basic understanding generated in this project will have the following wider beneficiaries and resulting impacts:

Healthcare and Medicine
Understanding the pathway for the production of bacterial sphingolipids will benefit clinicians and dentists interested in the effect of the oral microbiota on the progression of periodontitis. The role of bacterial sphingolipids in human and animal health will be explored with our project partners Davey and Ley, and this work will have impacts for clinicians working on the interplay between the gut microbiota and the development of the host immune system. This research may inform policy on recommendations for diet and supplementation to mitigate the role of the microbiota on periodontitis and auto-immune gut diseases, such as Crohn's disease.
Patient advocacy groups could benefit through direct access to knowledge and expertise generated in this project to inform clinical trials and treatments for diseases related to sphingolipid biosynthesis and autoimmune conditions. An example of the type of group who would benefit is the Deater Foundation. This charity seeks to research a neuropathy caused by mutations in the human sphingolipid biosynthesis pathway and access to research into this, has directly led to clinical trials of amino-acid supplementation as a targeted therapy against the clinical presentations of their specific mutations in this pathway.

Pharmaceutical Companies
The identification of the unique enzymes responsible for the various stages of the bacterial sphingolipid biosynthesis pathway and their structural characterisation will present novel drug targets for the development of new compounds to interfere with their action. Companies and researchers working in the pharmaceutical industry and in medicinal chemistry will therefore benefit from the knowledge created in this project.

Industrial biotechnology
Sphingolipids and their precursors have a high value as research tools in academic, clinical and industrial laboratories. But due to the difficulty associated with producing and isolating them from their native organisms they are extremely costly. Through understanding the bacterial sphingolipid pathway, we will produce knowledge that will allow the development of industrial strains optimised for the production of large quantities of sphingolipids and ceramides. The development of robust production hosts and lipid isolation methods by industrial biotechnology companies (e.g. Avanti) will have significant economic and scientific impacts.

Microbiome/Microbiota Industry
The biotechnology industry that has grown around microbiome/microbiota research is in an embryonic stage at present, but by 2025 is estimated to be worth up to $10bn. While there are currently no directly marketed microbiome/microbiota modifying drugs, there are many companies actively working in the pre-clinical and clinical stages of development. Furthermore, many companies are working in the neutraceutical and probiotic spaces. Our research will open possibilities to develop drugs to manipulate the production of sphingolipids in the human and animal microbiota; it will also inform the development of neutraceuticals and probiotics to stimulate, or inhibit, sphingolipid biosynthesis.